Lortan Tablet 50 mg
II. INDICATIONS
Hypertension
LORTAN is indicated for the treatment of hypertension.
Hypertensive Patients with Left Ventricular Hypertrophy
LORTAN is indicated for the reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy (see RACE – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal Protection in Type 2 Diabetic Patients with Proteinuria
LORTAN is indicated to delay the progression of renal disease as measured by a reduction in the incidence of doubling of serum creatinine and end stage renal disease (need for dialysis or renal transplantation), and to reduce proteinuria.
IV. CONTRAINDICATIONS
LORTAN is contraindicated in patients who are hypersensitive to any component of this product.
The concomitant use of LORTAN with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73m2) (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
III. DOSAGE AND ADMINISTRATION
LORTAN may be administered with or without food.
LORTAN may be administered with other antihypertensive agents.
Hypertension
The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3–6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered (see PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
No initial dosage adjustment is necessary for elderly patients up to 75 years of age, or for patients with mild renal impairment. For patients above 75 years of age, patients with moderate to severe renal impairment and patients on dialysis, a lower starting dose of 25 mg is recommended. A lower dose should be considered for patients with a history of hepatic impairment (see PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Reduction in the Risk of Stroke in Hypertensive Patients with Left Ventricular Hypertrophy
The usual starting dose is 50 mg of LORTAN once daily. A low dose of hydrochlorothiazide should be added and/or the dose of LORTAN should be increased to 100 mg once daily based on blood pressure response.
Renal Protection in Type 2 Diabetic Patients with Proteinuria
The usual starting dose is 50 mg once daily. The dose may be increased to 100 mg once daily based on blood pressure response. LORTAN may be administered with other antihypertensive agents (e.g., diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycemic agents (e.g., sulfonylureas, glitazones and glucosidase inhibitors).
